Citalopram Provides Little or No Benefit in Nondepressed Patients With Irritable Bowel Syndrome

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 1, 2010, Pages

  Ladabaum, Uri ^a,b   Sharabidze, Annie ^a,b   Levin, Theodore R ^c   Zhao, Wei K ^c   Chung, Elaine ^c   Bacchetti, Peter ^b   Jin, Chengshi ^b   Grimes, Barbara ^b   Pepin, Craig J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d Polyclinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BAROSTAT; BODY IMAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; HUMAN; IRRITABLE COLON; MALE; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSATION; SYMPTOM; TREATMENT DURATION;

EID: 72049107445     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.09.008     Document Type: Article

References (31)

1. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 104 (2009) s1-s35
2. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 123 (2002) 2108-2131
3. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 122 (2002) 1500-1511
4. Gralnek I.M., Hays R.D., Kilbourne A., et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119 (2000) 654-660
5. Hahn B.A., Yan S., and Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 60 (1999) 77-81
6. Clouse R.E., Lustman P.J., Geisman R.A., et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 8 (1994) 409-416
7. Jackson J.L., O'Malley P.G., Tomkins G., et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108 (2000) 65-72
8. Ford A.C., Talley N.J., Schoenfeld P.S., et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58 (2009) 367-378
9. Verdu B., Decosterd I., Buclin T., et al. Antidepressants for the treatment of chronic pain. Drugs 68 (2008) 2611-2632
10. Drossman D.A., Toner B.B., Whitehead W.E., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125 (2003) 19-31
11. Kuiken S.D., Tytgat G.N., and Boeckxstaens G.E. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 1 (2003) 219-228
12. Tabas G., Beaves M., Wang J., et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 99 (2004) 914-920
13. Vahedi H., Merat S., Rashidioon A., et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 22 (2005) 381-385
14. Tack J., Broekaert D., Fischler B., et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55 (2006) 1095-1103
15. Talley N.J., Kellow J.E., Boyce P., et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 53 (2008) 108-115
16. Whitehead W.E., Palsson O., and Jones K.R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 122 (2002) 1140-1156
17. Mertz H., Naliboff B., Munakata J., et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109 (1995) 40-52
18. Azpiroz F., Bouin M., Camilleri M., et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 19 (2007) 62-88
19. Camilleri M. Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut 51 Suppl 1 (2002) i34-i40
20. Mayer E.A., Bradesi S., Chang L., et al. Functional GI disorders: from animal models to drug development. Gut 57 (2008) 384-404
21. Whitehead W.E., Diamant N., Meyer K., et al. Pain thresholds measured by the barostat predict the severity of clinical pain in patients with irritable bowel syndrome. (abstr). Gastroenterology 114 (1998) A858
22. Kuiken S.D., Lindeboom R., Tytgat G.N., et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 22 (2005) 157-164
23. Izquierdo S., Rey E., Garcia Alonso M., et al. Has the identification of rectal hypersensitivity any implication in the clinical outcome of irritable bowel syndrome?. Rev Esp Enferm Dig 97 (2005) 223-228
24. Zar S., Benson M.J., and Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol 18 (2006) 151-158
25. Drossman D.A., Corazziari E., and Talley N.J. Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus (2000), Degnon Associates, McLean, VA
26. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134 (2001) 657-662
27. Mangel A.W., Hahn B.A., Heath A.T., et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 26 (1998) 76-81
28. Camilleri M., Chey W.Y., Mayer E.A., et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 161 (2001) 1733-1740
29. Camilleri M., Northcutt A.R., Kong S., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355 (2000) 1035-1040
30. Drossman D.A., Patrick D.L., Whitehead W.E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 95 (2000) 999-1007
31. Andresen V., Montori V.M., Keller J., et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 6 (2008) 545-555